Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples